Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
Acta Med Croatica
; 53(2): 79-82, 1999.
Article
in En
| MEDLINE
| ID: mdl-10705625
ABSTRACT
Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile. The aim of this single blind, randomized clinical trial was to compare the efficacy of pantoprazole (PAN) 40 mg/day and omeprazole (OME) 20 mg/day in patients with grade I and II GERD (Savary-Miller classification). A total of 120 patients were included (PAN = 60 and OME = 60). In the per protocol/analysis, healing rates at 4 weeks were 76.3% PAN and 71.2% OME (ns), and at 8 weeks 94.7% PAN and 92.9% OME (ns). In the intention to treat analysis, healing rates at 4 weeks were 75% PAN and 70% OME (ns), and at 8 weeks 90% PAN and 86.6% OME (ns). Both pantoprazole and omeprazole were well tolerated with no serious drug related adverse events. Pantoprazole 40 mg/day was found to be safe and effective therapy comparable to omeprazole 20 mg/day in the short-term treatment for reflux esophagitis (grade I and II).
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sulfoxides
/
Benzimidazoles
/
Omeprazole
/
Esophagitis, Peptic
/
Anti-Ulcer Agents
Type of study:
Clinical_trials
/
Guideline
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Acta Med Croatica
Journal subject:
MEDICINA
Year:
1999
Type:
Article
Affiliation country:
Croatia